Skip to main content
Top
Published in: Supportive Care in Cancer 12/2008

Open Access 01-12-2008 | Short Communication

Treatment adherence and patients’ acceptance of home infusions with adenosine 5′-triphosphate (ATP) in palliative home care

Authors: Sandra Beijer, Nicole E. G. Wijckmans, Erik van Rossum, Cor Spreeuwenberg, Ron A. G. Winkens, Lisette Ars, Pieter C. Dagnelie

Published in: Supportive Care in Cancer | Issue 12/2008

Login to get access

Abstract

Goals of work

In preterminal cancer patients, provision of palliative care in the patients’ own environment is preferred. The aim of the present study was to evaluate patients’ and caregivers’ treatment adherence and patients’ acceptance of home infusions with adenosine 5′-triphosphate (ATP).

Patients and methods

Preterminal cancer patients (life expectancy <6 months) with mixed tumor types were eligible for the study. Patients received a maximum of eight weekly intravenous 8–10 h ATP infusions. Evaluation of treatment adherence was based on registration of protocol deviations and patients’ acceptance by structured interviews with patients.

Main results

Fifty-one patients received a total of 266 intravenous ATP infusions. The infusion protocol was well executed: mean duration ≈8.30 h, stepwise achievement of the maximum infusion rate within 30 min in 65% of the infusions, and almost no delay in weekly administration. All except one patient were not burdened by the administration of the infusions at home and none of them had felt afraid. The majority of patients found the advantages of the ATP infusions outweighing the disadvantages. However, an important bottleneck in the administration of ATP infusions at home was difficulty in establishing venous access.

Conclusion

ATP infusions at home are well accepted by patients. Difficulties in establishing venous access might be reduced by composing specialized home infusion teams working both at the day care center and at home or by adopting an alternative route of venous access.
Literature
3.
go back to reference Agteresch HJ, Dagnelie PC, van Der Gaast A, Stijnen T, Wilson JH (2000) Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:321–328 doi:10.1093/jnci/92.4.321 PubMedCrossRef Agteresch HJ, Dagnelie PC, van Der Gaast A, Stijnen T, Wilson JH (2000) Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:321–328 doi:10.​1093/​jnci/​92.​4.​321 PubMedCrossRef
4.
go back to reference Agteresch HJ, Rietveld T, Kerkhofs LG, van den Berg JW, Wilson JH, Dagnelie PC (2002) Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 20:371–378 doi:10.1200/JCO.20.2.371 PubMedCrossRef Agteresch HJ, Rietveld T, Kerkhofs LG, van den Berg JW, Wilson JH, Dagnelie PC (2002) Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 20:371–378 doi:10.​1200/​JCO.​20.​2.​371 PubMedCrossRef
5.
go back to reference Beijer S, Gielisse EA, Hupperets PS, van den Borne BE, van den Beuken-van Everdingen M, Nijziel MR et al (2007) Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients. Invest New Drugs 25:571–579 doi:10.1007/s10637-007-9076-1 PubMedCrossRef Beijer S, Gielisse EA, Hupperets PS, van den Borne BE, van den Beuken-van Everdingen M, Nijziel MR et al (2007) Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients. Invest New Drugs 25:571–579 doi:10.​1007/​s10637-007-9076-1 PubMedCrossRef
6.
go back to reference Beijer S, van Rossum E, Hupperets PS, Spreeuwenberg C, van den Beuken M, Winkens RA et al (2007) Application of adenosine 5′-triphosphate (ATP) infusions in palliative home care: design of a randomized clinical trial. BMC Public Health 7:4 doi:10.1186/1471-2458-7-4 PubMedCrossRef Beijer S, van Rossum E, Hupperets PS, Spreeuwenberg C, van den Beuken M, Winkens RA et al (2007) Application of adenosine 5′-triphosphate (ATP) infusions in palliative home care: design of a randomized clinical trial. BMC Public Health 7:4 doi:10.​1186/​1471-2458-7-4 PubMedCrossRef
7.
go back to reference Borras JM, Sanchez-Hernandez A, Navarro M, Martinez M, Mendez E, Ponton JL et al (2001) Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial. BMJ 322:826–830 doi:10.1136/bmj.322.7290.826 PubMedCrossRef Borras JM, Sanchez-Hernandez A, Navarro M, Martinez M, Mendez E, Ponton JL et al (2001) Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial. BMJ 322:826–830 doi:10.​1136/​bmj.​322.​7290.​826 PubMedCrossRef
8.
go back to reference Chataway J, Porter B, Riazi A, Heaney D, Watt H, Hobart J et al (2006) Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial. Lancet Neurol 5:565–571 doi:10.1016/S1474-4422(06)70450-1 PubMedCrossRef Chataway J, Porter B, Riazi A, Heaney D, Watt H, Hobart J et al (2006) Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial. Lancet Neurol 5:565–571 doi:10.​1016/​S1474-4422(06)70450-1 PubMedCrossRef
12.
go back to reference Haskell CM, Mendoza E, Pisters KM, Fossella FV, Figlin RA (1998) Phase II study of intravenous adenosine 5′-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs 16:81–85 doi:10.1023/A:1006018610986 PubMedCrossRef Haskell CM, Mendoza E, Pisters KM, Fossella FV, Figlin RA (1998) Phase II study of intravenous adenosine 5′-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs 16:81–85 doi:10.​1023/​A:​1006018610986 PubMedCrossRef
15.
16.
go back to reference Linthorst GE, Vedder AC, Ormel EE, Aerts JM, Hollak CE (2006) Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands. Nephrol Dial Transplant 21:355–360 doi:10.1093/ndt/gfi221 PubMedCrossRef Linthorst GE, Vedder AC, Ormel EE, Aerts JM, Hollak CE (2006) Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands. Nephrol Dial Transplant 21:355–360 doi:10.​1093/​ndt/​gfi221 PubMedCrossRef
20.
go back to reference Zimran A, Hollak CE, Abrahamov A, van Oers MH, Kelly M, Beutler E (1993) Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood 82:1107–1109PubMed Zimran A, Hollak CE, Abrahamov A, van Oers MH, Kelly M, Beutler E (1993) Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood 82:1107–1109PubMed
Metadata
Title
Treatment adherence and patients’ acceptance of home infusions with adenosine 5′-triphosphate (ATP) in palliative home care
Authors
Sandra Beijer
Nicole E. G. Wijckmans
Erik van Rossum
Cor Spreeuwenberg
Ron A. G. Winkens
Lisette Ars
Pieter C. Dagnelie
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 12/2008
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0504-3

Other articles of this Issue 12/2008

Supportive Care in Cancer 12/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine